The Decision upon Rehearing in Amgen, Inc. v. Human Genome Sciences, Inc. (HGS) – Interference 105,613 – Teaching Points upon Interference Practice By Rick Neifeld 1

     A preference upon rehearing in this division antiquated 6/5/2009 was published 7/1/2009 onthe “Informative Opinions” territory of a Board of Patent Appeals as well as Interferences (BPAI) website. See http://www.uspto.gov/web/offices/dcom/bpai/informative_opinions.html . APJsTorczon, Lane, Tierney participated in a decision. APJ Torczon rendered a decision.

     The role of a BPAI ominous opinions is to yield superintendence to a viewable bar.This sold perspective provides superintendence upon factors which come in in to a preference for rehearing as well as a option of a BPAI per what issues it will decide. However, it additionally providesanother use tip (or trap for a unwary) in division practice.

     Amgen was in a division upon an focus as well as HGS was in a division upon a patent. Judgement was entered opposite HGS in reply to an Amgen suit alleging all concerned HGS claims unpatentable for miss of utility. All alternative motions were dismissed. HGS sought rehearing for a role of looking a preference upon dual of a discharged motions opposite Amgen, HGS motions 2 as well as 4. HGS did not, in a ask for rehearing, competition a preference land a claims not in in utility. In reply to HGS’s ask for rehearing, a row reconsidered, though again motionless not to confirm HGS’s motions 2 as well as 4. As a result, a Amgen focus is or will be returned to ex parte prosecution, as well as HGS will not be means to experience lay away partes in conference of a Amgen application.

     HGS suit 2 was in actuality a suit for an sequence to uncover means since settlement should not be entered opposite Amgen for unwell to prima facie uncover priority. As to this motion, a preference states which “There is no longer a need to finalise priority so there is no longer a need to emanate an sequence to uncover means opposite Amgen.”

     HGS suit 4 was a suit for settlement which all of Amgen’s concerned claims were unpatentable as viewable formed upon HGS’s concerned patent. However, a APJ paid in instalments this suit to a priority proviso since it concerned antedating over HGSs concerned patent, as well as thus this suit was not briefed in a rough motions phase. As to this motion, a preference states which “Granting HGS suit 4 though needing an antithesis could lift poignant due routine problems, whilst move with a lecture as well as in attendance evidentiaryprocesses would check visualisation multiform months.”

     Accordingly, since HGS was not entitled to record or short a motions 2 as well as 4; they have been right away a nullity.

     There is a single some-more revelation point, as well as use tip, issuing from this decision. Note which HGS was close out of lay away partes conference of a Amgen focus in perspective of a settlement terminating a interference. That is obviously not what HGS wanted, as well as it did not have to finish which way. Reading in between a lines, it appears which a customary for assembly a focus sequence was an emanate for both parties. However, HGS unsuccessful to lift which emanate around rough motions. Instead, it usually lifted it during a write discussion call per deferral of sure motions. On this point, a preference states that:

     At a write conference for a deferral request, HGS voiced regard which Amgen’s antedating bid competence be unsuitable with Amgen’s suit opposite HGS upon utility. It is value observant during this indicate which HGS did not record a own suit for visualisation opposite Amgen for miss of utility, which would not have been theme to an antedating effort. The deferral sequence available HGS, in a eventuality of “judgment upon a basement of an inauspicious preference upon utility, [to] lift a regard during which time as a reason not to ensue rught away to judgment.” Therequest for rehearing is an suitable car to lift a regard again, though therequest contingency mount or tumble upon a own merits. At a write conference for a deferral request, HGS voiced concernthat Amgen’s antedating bid competence be unsuitable with Amgen’s suit opposite HGS upon utility. It is value observant during this indicate which HGS did not record a own suit for visualisation opposite Amgen for miss of utility, which would not have been theme to an antedating effort. The deferral sequence available HGS, in a eventuality of “judgment upon a basement of an inauspicious preference upon utility, [to] lift a regard during which time as a reason not to ensue rught away to judgment.” Therequest for rehearing is an suitable car to lift a regard again, though therequest contingency mount or tumble upon a own merits.

     What HGS could have done, though assumingly did not do, was, upon identifying which “Amgen’s antedating bid competence be unsuitable with Amgen’s suit opposite HGS upon utility,” ask leave to belatedly record a suit opposite Amgen upon which basis. And if such leave was denied, timely ask rehearing. If HGS had timely changed for settlement upon a basement of miss of focus of Amgen’s application, (for e.g. upon a basement which Amgen’s pre division showings were unsuitable with Amgen’s suit for miss of utility), which could have scored equally a antedating emanate as well as a focus emanate together, requiring (or during slightest favoring) their point briefing, possibly during a rough motions proviso or priority phase. Instead, HGS assumingly concluded to merely be entitled to “raise a concern” about Amgen’s utility, in reply to inauspicious settlement opposite HGS, as well as obviously which was, in hindsight, deficient relief.

1. we was a chair of a AIPLA Interference Committee from 2000-2002, as well as Deputy conduct of a Interference Section during Oblon Spivak, for multiform years. we can be reached around write during 703-415-0012 or around a organisation web site, http://www.Neifeld.com.